Publicacions (16) Publicacions de XANDO DÍAZ VILLAMARÍN

2024

  1. Novel Genetic Variants Explaining Severe Adverse Drug Events after Clinical Implementation of DPYD Genotype-Guided Therapy with Fluoropyrimidines: An Observational Study

    Pharmaceutics, Vol. 16, Núm. 7

  2. Selective Digestive Decontamination: A Comprehensive Approach to Reducing Nosocomial Infections and Antimicrobial Resistance in the ICU

    Journal of Clinical Medicine, Vol. 13, Núm. 21

2023

  1. A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study

    The Lancet, Vol. 401, Núm. 10374, pp. 347-356

  2. Azathioprine dose tailoring based on pharmacogenetic information: Insights of clinical implementation

    Biomedicine and Pharmacotherapy, Vol. 168

  3. Economic evaluation of pharmacogenomic-guided antiplatelet treatment in Spanish patients suffering from acute coronary syndrome participating in the U-PGx PREPARE study

    Human Genomics, Vol. 17, Núm. 1

2022

  1. Genetic Polymorphisms in VEGFR Coding Genes (FLT1/KDR) on Ranibizumab Response in High Myopia and Choroidal Neovascularization Patients

    Pharmaceutics, Vol. 14, Núm. 8

  2. Pharmacogenetics of siponimod: A systematic review

    Biomedicine and Pharmacotherapy, Vol. 153

  3. Pharmacogenomics decision support in the U-PGx project: Results and advice from clinical implementation across seven European countries

    PLoS ONE, Vol. 17, Núm. 6 6

2021

  1. Genetic polymorphisms affecting ranibizumab response in high myopia patients

    Pharmaceutics, Vol. 13, Núm. 11

  2. Pharmacogenetic polymorphisms affecting bisoprolol response

    Biomedicine and Pharmacotherapy, Vol. 142

2020

  1. Genetic variants affecting anti-vegf drug response in polypoidal choroidal vasculopathy patients: A systematic review and meta-analysis

    Genes, Vol. 11, Núm. 11, pp. 1-13

2019

  1. Cost-effectiveness analysis of pharmacogenomics-guided clopidogrel treatment in Spanish patients undergoing percutaneous coronary intervention

    Pharmacogenomics Journal, Vol. 19, Núm. 5, pp. 438-445

  2. Pharmacogenetics in the Treatment of Cardiovascular Diseases and its current progress regarding Implementation in the Clinical Routine

    Genes, Vol. 10, Núm. 4

2016

  1. A new pharmacogenetic algorithm to predict the most appropriate dosage of acenocoumarol for stable anticoagulation in a mixed Spanish population

    PLoS ONE, Vol. 11, Núm. 3

  2. Genetic polymorphisms influence on the response to clopidogrel in peripheral artery disease patients following percutaneous transluminal angioplasty

    Pharmacogenomics, Vol. 17, Núm. 12, pp. 1327-1338

  3. Results of genotype-guided antiplatelet therapy in patients who undergone percutaneous coronary intervention with stent

    International Journal of Cardiology, Vol. 225, pp. 289-295